Tarian Gel:
A Topical Approach
to Skin Toxicity Prevention
in Oncology

Discover Tarian Gel

An Innovative Approach
to Skin Toxicities Prevention
in Oncology

Woman Patient I Tarian Pharma I At Home putting Tarian Gel on arm
AI-generated to protect patients' privacy
What It Is

Tarian Gel: A Topical Brimonidine Tartrate Gel for Oncology Supportive Care

At Tarian Pharma, we believe that supportive care deserves the same attention as primary cancer treatment. Tarian Gel is being developed to help prevent treatment-related skin toxicities before they affect patient comfort, adherence, and treatment continuity.

Our ambition is clear: to transform the skin toxicity management in oncology through a topical, science-based approach designed around prevention, protocol integration, and patient quality of life.

We aim for a future where every cancer treatment journey is supported from the surface to the core where healing doesn’t come at the cost of dignity, pain, or isolation.

Our ambition is to make holistic cancer care the standard, addressing both the disease and the physical and emotional impact of cancer treatment.

How It Works

Developed with Oncologists and Designed for Oncology Patients

Cancer diagnosis and treatment can place a significant physical and emotional burden on patients. Tarian Gel is designed to integrate into oncology care pathways and daily life with the aim of supporting treatment continuity while limiting additional burden.

Maximize cancer treatment outcome I Tarian Pharma

Support treatment continuity

Insignificant systemic exposure
Insignificant systemic exposure
Easily included into cancer therapy

Designed for oncology protocols

Excellent local tolerance
Excellent local tolerance
Comfortable home use

Once-daily home application

Eases patient journey
Eases patient journey
Woman Patient I Tarian Pharma I Standing shaking doctor hand
AI-generated to protect patients' privacy
Tarian Gel Protection Is Power
Why It Matters

Skin Toxicity Prevention Matters in Oncology

Dermatological side effects are among the most frequent and disruptive complications of cancer treatment. Rashes, burns, folliculitis, hairloss and painful skin reactions can lead to emotional distress, social withdrawal, and, in too many cases, treatment interruption.
We believe that skin protection should be proactive, not reactive.
Tarian Gel is the result of more than 200 formulation prototypes developed and refined by experts in dermatology and pharmaceutical science.

Tarian Gel is designed to be:

  • Supported by clinical evaluation for safety and tolerability
  • Designed around the needs of patients and physicians
  • Developed to address a significant unmet clinical need, not as a cosmetic workaround

Its development aims to support treatment continuity, patient wellbeing, and the dignity of care.

Mechanism of Action

How Tarian Gel Works:
Localized Vasoconstriction

Tarian Gel mimics the protective mechanism of cooling devices by inducing controlled, localized vasoconstriction in superficial cutaneous blood vessels.

This pharmacological approach is intended to reduce skin exposure to anticancer agents without the pain and logistical limitations associated with physical cooling.

By modulating cutaneous microcirculation, Tarian Gel reduces local skin exposure to chemotherapeutic agents and help prevent treatment-related dermatologic adverse events.

The active ingredient, brimonidine tartrate, is a selective alpha-2 adrenergic receptor agonist responsible for this vasoconstrictive effect.

TAR-0520 is an investigational medicinal product. It has not been approved for commercial use. The information provided on this website is intended for general informational purposes only and does not constitute medical advice or promotional communication.